On Thursday, Hims & Hers Health Inc. (NYSE:HIMS) announced Thursday an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk A/S’ (NYSE:NVO) Wegovy.
Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month.
The new Compounded Semaglutide Pill is formulated to protect the active ingredient during digestion and to support absorption.
In 2025, Hims & Hers doubled its facility footprint to over one million square feet, integrating advanced pharmacy capabilities, lab testing, and R&D space.
Hims & Hers said it adheres to all applicable federal and state regulatory standards for compounding.
Novo Nordisk Legal Claims
Soon after, Novo Nordisk issued a statement regarding the announcement by Hims & Hers.
Novo Nordisk stock is already under pressure on a softer outlook for fiscal 2026.
The Dutch pharma giant said Hims & Hers will unlawfully mass-market an unapproved, inauthentic, and untested knockoff semaglutide pill.
“The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action…” This is another example of Hims & Hers’ historic behaviour of duping the American public with knockoff GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knockoffs.”
Only Novo Nordisk manufactures an FDA-approved Wegovy pill formulated with SNAC technology, which facilitates semaglutide absorption when administered orally.
The Wegovy pill is available in all doses, in full supply. Compounded semaglutide is not approved by the FDA and may contain impurities, unnecessary additives, and untested doses, Novo Nordisk said on Thursday.
Why It Matters
In June 2025, Hims & Hers’ stock cratered almost 30% when Novo Nordisk discontinued working with the company in relation to direct access to Wegovy (semaglutide).
Novo Nordisk alleged that Hims & Hers Health failed to adhere to the law prohibiting mass sales of compounded drugs under the false guise of “personalization” and is disseminating deceptive marketing that risks patient safety.
Price Action: Hims & Hers Health shares were down 1.85% at $23.94, and Novo Nordisk shares were down 5.98% at $44.37 at the time of publication on Thursday, according to Benzinga Pro data.
Image by KK Stock via Shutterstock
Recent Comments